Increased C/EBPβ was previously reported to interact with transcription factors GATA4 and NFAT;[21, 24, 25, 26] the latter ones induce a genetic program associated with pathological cardiac hypertrophy such as upregulated BNP, β‐MHC, skeletal α‐Actin, and cardiac α‐Actin and downregulated α‐MHC and SERCA.[27] To further elucidate how HIPK1 and C/EBPβ in cardiomyocytes mediate detrimental effects during pathological hypertrophy, we first demonstrated that C/EBPβ could interact with GATA4 and NFAT3 in cardiomyocytes using co‐immunoprecipitation assay (Figure 4e). The gene discussed is HIPK1; the disease is cardiac hypertrophy.